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Abstract Purpose to evaluate the agreement between the clinical and pathological stagings of
breast cancer based on clinical and molecular features.
Methods this was a cross-sectional study, in which clinical, epidemiological and
pathological data were collected from 226 patients who underwent surgery at the
Prof. Dr. José Aristodemo Pinotti Women’s Hospital (CAISM/Unicamp) from January 2008
to September 2010. Patients were staged clinically and pathologically, and were classified
as: understaged, when the clinical staging was lower than the pathological staging;
correctly staged, when the clinical staging was the same as the pathological one; and
overstaged, when the clinical staging was greater than the pathological staging.
Results understaged patients were younger (52.2 years; p < 0.01) and more symp-
tomatic at diagnosis (p ¼ 0.04) when compared with correctly or overstaged patients.
Clinicopathological surrogate subtype, menopausal status, parity, hormone replace
therapy and histology were not associated with differences in staging. Women under
57 years of age were clinically understaged mainly due to underestimation of T (tumor
staging) (p < 0.001), as were the premenopausal women (p < 0.01). Patients whose
diagnosis was made due to clinical complaints, and not by screening, were clinically
understaged due to underestimation of N (lymph nodes staging) (p < 0.001).
Conclusion the study shows that the clinicopathological surrogate subtype is not
associated with differences in staging, while younger women diagnosed because of
clinical complaints tend to have their breast tumors understaged during clinical
evaluation.
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Introduction
The staging of breast cancer involves an adequate assessment
of the local and distant extensions of the disease. In the age of
precision medicine, clinical tumor staging must be very
accurate in order to avoid inadequate treatment. For in-
stance, data from the American College of SurgeonsOncology
Group (ACOSOG) and the National Surgical Adjuvant Breast
and Bowel Project (NSABP) most recent trials, as well as the
EuropeanOrganization for Research and Treatment of Cancer
(EORTC) AMAROS (AfterMapping of the Axilla: Radiotherapy
or Surgery) and a few other trials defined very conservative
approaches to women with early stage breast cancer1–3; it
seems sensible, however, that these advantages may not be
enjoyed by women whose tumors have been understaged
during pretreatment clinical evaluation.
The currently available methods for breast cancer clinical
staging rely on physical examination and radiologic assess-
ment of the breast.4 It is well known that several factors may
interfere with clinical breast examination (CBE), such as
breast density and volume, and women’s menstrual status.5
The same applies tomammography, sincebreast densitymay
compromise exam accuracy, for example.6 Moreover, recent
studies have suggested that low-grade luminal A tumors are
generally detected with screening, whereas rapidly growing
tumors may be detected only when they become symptom-
atic,7 which implies that the molecular subtype of breast
cancer may be associated with clinical presentation and
thence with the sensitivity of the clinical and radiological
assessments. Current staging guidelines, however, do not
suggest staging procedures tailored according to molecular
subtype.
It remains unknown to what extent the characteristics of
patients and their tumors may hamper a correct presurgical
evaluation of the breast cancer stage. In this study, we
examined whether factors such as clinicopathological surro-
gate subtypes, age, menopause status, and diagnosis by
screening or symptoms are associated with the discrepancy
between the clinical and pathological stagings of breast
tumors in women unaware of the existence of treatment.
Methods
Study Design
We performed a secondary analysis of data collected from
other studies linked to our study group.8–12 The principal
investigator (Juliana Pinho Espinola – JPE) conducted a
further review of 226 medical records, specifically for the
present report, in order to obtain data regarding clinical
staging, exams, and pathological staging. Clinical and epide-
miological data are from January 2008 to September 2010.
Data were collected at Professor Dr. José Aristodemo Pinotti
Women’s Hospital (CAISM/Unicamp). In this study, data
pertaining to the molecular and pathological characteristics
of the tumors had already been obtained for the studies cited
above.
Resumo Objetivo avaliar a concordância entre o estadiamento clínico e patológico do câncer
de mama em função das características clínicas e moleculares das pacientes.
Métodos estudo de corte transversal, sendo coletados dados clínicos, epidemioló-
gicos e anátomo-patológicos de 226 pacientes operadas no Hospital daMulher Prof. Dr.
José Aristodemo Pinotti (Centro de Atenção Integral à Saúde da Mulher – CAISM/
Unicamp), de janeiro de 2008 a setembro de 2010. As pacientes foram estadiadas
clínica e patologicamente e classificadas como: subestadiadas, quando o estadiamento
clínico foi menor do que o patológico; corretamente estadiadas, quando o estadia-
mento clínico foi equivalente ao patológico; e superestadiadas, quando o estadia-
mento clínico foi maior do que o patológico.
Resultados as pacientes subestadiadas eram mais jovens (52,2 anos; p < 0,01) e
sintomáticas ao diagnóstico (p ¼ 0,04) do que as pacientes corretamente estadiadas
ou superestadiadas. O subtipo clinico-patológico, o status menopausal, a paridade, a
terapia de reposição hormonal e a histologia não foram associados com a diferença no
estadiamento. Detectamos que as mulheres com menos de 57 anos de idade foram
clinicamente subestadiadas principalmente devido à subestimação do T (p < 0,001),
assim como as mulheres na pré-menopausa (p < 0,01). Por outro lado, as pacientes
cujo diagnóstico foi realizado por queixa clínica, e não rastreamento, foram clinica-
mente subestadiadas devido à subestimação do N (p < 0,001).
Conclusão o estudo nosmostra que o subtipo clinico-patológico não está associado a
diferenças de estadiamento, enquanto mulheres mais jovens, e que tiveram seu
diagnóstico por queixa clínica, tendem a ter seus tumores mais frequentemente
subestadiados.
Palavras-chave
► câncer de mama
► estadiamento do
câncer
► mamografia
► neoplasmas
► mama
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Inclusion criteria consisted of: women undergoing pri-
mary surgical treatment for breast cancer; invasive ductal
carcinoma or invasive lobular carcinoma; histological sam-
ples that could provide material for the safe and accurate
diagnosis of cancer, and the information about its stage for
this study. Exclusion criteria consisted of: lack of information
about the staging or the molecular features of the tumor
(technical inability to perform any of the laboratory proce-
dures); patients undergoing neoadjuvant chemotherapy;
patients with metastatic breast cancer; patients already
treated for breast cancer before their entry into the study.
Data Collection
Information about the epidemiology, clinical and pathologi-
cal staging, and surgical treatment performedwere reviewed
and annotated in a specific form. The review of the medical
records was performed only by the main investigator, reduc-
ing the potential for bias in the interpretation of the infor-
mation contained in the medical reports. The data collection
form was initially used to evaluate 20 medical records, and
the information was entered into the pre-existing database,
allowing the adjustment of both the collection record and the
database, which was formatted to contain all information
relevant to this study.
Information pertaining to the clinical staging was ob-
tained from the patient’s initial appointment after the
histological diagnosis had been confirmed. All patients
were evaluated by a breast surgeon, and the staging of the
disease was done according to well-established protocols
(such as the American Joint Commission on Cancer –AJCC –
protocol).13Women underwent two-incidence digital mam-
mographies, craniocaudal (CC) and mediolateral oblique
(MLO). Breast ultrasound was used when needed. Clinical
lymph nodes status was determined with palpation of the
axilla. All pathological reports were reviewed by JPE. Evalu-
ation of the expression of estrogen/progesterone receptors
HER2 and Ki67was performed using immunohistochemistry
and fluorescent in situ hybridization (FISH) according to
standard protocols. All pathological assessments were per-
formed at the Experimental Pathology Laboratory of CAISM/
Unicamp. The surrogate molecular subtypes of breast cancer
were determined according to the 13th St. Gallen
Consensus.14
Classification of Staging Status
Patients were classified as: understaged, when the clinical
staging was lower than the pathological staging; correctly
staged, when the clinical staging was the same as the
pathological staging; and overstaged, when the clinical
staging was greater than the pathological staging.
Data Analysis
Datawere analyzed using the R statistical package for micro-
computers (R Development Core Team, 2015, Aalborg,
Denmark). The significance level was 5% (p  0.05 and
confidence interval of 95%). Bivariate analysis consisted of
calculating the kappa value for agreement between the
clinical and pathological stagings. Cases were classified as:
understaged, if the clinical staging was less than pathologi-
cal; correctly staged, if both matched; and overstaged, if the
clinical staging was higher than pathological (we call these
conditions “staging statuses”). A logistic regression model
was adjusted to determine possible associations between the
congruence of staging and the clinical and pathological
features of the tumors. Finally, we separately analyzed
whether the molecular subtype of breast cancer was associ-
ated with staging status using the Chi-square (2) test.
Results
Eighty-six (38%) patients were understaged, 130 (57.5%)
patients were correctly staged, and 10 (4.5%) patients were
overstaged. In ►Table 1, we compare clinical and pathologi-
cal characteristics according to staging status (understaged,
correctly staged/overstaged). For the statistical analysis,
patients who were correctly staged and overstaged were
grouped. Patients understaged were younger (mean age at
diagnosis ¼ 52.2 years; p < 0.0001) and more symptomatic
at diagnosis (p ¼ 0.04) than their counterparts (mean age at
diagnosis ¼ 60.7 years). Menopausal status, parity, family
history of breast cancer, post-menopausal hormonal replace-
ment, histology (whether ductal or non-ductal) and body
mass index (BMI) were not associated with the staging
status. The affected breast quadrant was not related to the
discordance of the staging status (p ¼ 0.18, data not shown).
The mean time between the first appointment at the insti-
tution when clinical staging was performed and the surgery
was of 65 days for correctly and overstaged patients, and of
62 days for understaged patients (p ¼ 0.25; data not shown
in table).
►Table 2 cross-tabulates the clinical and pathological
staging of the women according to the 2010 AJCC consen-
sus13, and further dissects T (tumor) and N (lymph nodes)
stagings. Out of all women clinically considered as stage I, 32
were later considered as stage II (24 women) or stage III (8
women). From the group of women in stage II, 54 were later
considered as stage III, whereas 8 were downstaged. From
the stage III group, 2 were downstaged to stage II pathologi-
cal. Because all metastatic patients were excluded from the
analysis, there are no stage IV patients in this study. The
intraclass correlation coefficient (ICC) for AJCC staging agree-
ment was 0.54. While analyzing only T staging, ICC was
slightly superior (ICC ¼ 0.62). It is worth noting that the
agreement was negatively affected by 27 women who were
clinically T1, T2 or T3 and were later found to be pT4, due to
dermal involvement not seen in the clinical evaluation. The
mean pathological size of the tumor was also relevant in
understaged patients (mean 32 mm, range 12 to 80 mm) in
comparison to correctly staged and overstaged patients
(mean 25 mm, range 1 to 75 mm) (p < 0.001).
Restricting the analysis to N staging (ICC ¼ 0.33), agree-
ment was low mainly because of understaging of axillary
lymph nodes: out of the 137 N0 patients, 48 were later found
to harbor lymph node compromise. Also, patients with a
clinically positive axilla were often understaged: 41out of 85
N1 patients were actually pN2 or pN3. It was found that the
Rev Bras Ginecol Obstet Vol. 38 No. 5/2016
Molecular Subtype of Breast Cancer Unassociated with Clinical Under- or Overstaging of Breast Cancer Espinola et al. 241
understaged patients had a mean of 6.9 lymph node involve-
ment (range 0 to 41), and the correctly staged and overstaged
patients had a mean of 2.3 (range 0 to 29) (p < 0.001)
compromised nodes.
In►Table 3wefurther analyze the significant associations
described in ►Table 1, between staging status and age,
menopausal status, and whether diagnosis was made during
breast cancer screening or triggered by symptoms. We
arbitrarily established the cutoff point for this analysis as
the median age (57 years) of the patients. We detected that
women < 57 years of agewere clinically understagedmainly
due to underestimation of tumor volume or dermal involve-
ment (T) (p < 0.001). The same was true for premenopausal
women (p < 0.01), although these associations were not
significant after multivariate adjustment. On the other
hand, patients whose diagnosis was triggered by symptoms
were clinically understaged due to underestimation of their
N status (p < 0.001).
We also analyzed whether the type of surgery performed
(conservative or radical) was associated with the staging
status (p ¼ 0.33) and the rate of re-operation due to com-
promised surgical margins (p ¼ 0.45) (data not shown in
tables), but no relation was found.
In ►Table 4, we examine the staging status according to
the molecular subtype of the tumors (p ¼ 0.48). Thirty three
(38.4%) of the patients whose tumors were understaged had
luminal A tumors; 30 (34.9%) had luminal B; 13 (15.1%) had
HER2 positive, and 10 (11.6%) had triple-negative tumors.
Out of the patients whose tumors were overstaged, 4 (40%)
had luminal A; 3 (30%) luminal B; 1 (10%) HER2 positive; and
2 (20%) had triple-negative tumors. Out of the correctly
staged women, 47 (36%) had luminal A; 54 (41.5%) luminal
B; 9 (7%) had HER2 positive; and 20 (15.5%) had triple-
negative tumors.
Discussion
Our study suggests that the surrogate clinicopathological
subtype of breast tumor is not associated with the discrep-
ancies between clinical and pathological stagings, whereas
younger women and/or those with palpable tumors are at a
significantly higher risk of having their disease clinically
Table 1 Clinical and pathological features as related to staging status
Understaged Correctly staged/ Overstaged p-value p-value adjusted
Number of Patients (n/%) 86 (38) 140 (62)
Age (mean/SD) 52.2 (11.5) 60.7 (13.9) < 0.01 < 0.0001
Menopause (n/%)
No 34 (39.6) 35 (25)
Yes 52 (60.5) 105 (75) 0.02 0.06
Parity (n/%)
Nulliparous 8 (9.3) 23 (16.4)
1 or more offspring 78 (90.7) 117 (83.6) 0.16 
Family history of breast cancer (n/%)
Yes 14 (16.3) 27 (19.3)
No 72 (83.7) 113 (80.7) 0.59 
Diagnosis (n/%)
Screening 21 (24.4) 57 (40.7)
Symptomatic 65 (75.6) 83 (59.3) < 0.01 0.04
Hormonal therapy (n/%)
No 65 (76.5) 120 (85.7)
Yes 20 (23.5) 20 (14.3) 0.10 
BMI (n/%)
< 25 30 (34.9) 46 (32.9)
25–29.9 28 (32.6) 42 (30.0)
 30 28 (32.6) 52 (37.1) 0.79 
Histology (n/%)
Ductal 83 (96.5) 132 (94.3)
Lobular 3 (3.5) 8 (5.7) 0.54 
Abbreviation: BMI, body mass index; n, number; SD, standard deviation;
Note:  multicentric tumors not included (n ¼ 22).
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understaged. This may result in significant detrimental
effects for treatment planning in younger women, since
suboptimal treatments may be prescribed. Interestingly,
younger, premenopausal women had their tumors under-
staged mainly due to T underestimation, whereas women
with symptomatic tumors had their disease understaged
mainly due to N underestimation.
It is important to notice that CBE workup may vary
according to practitioner experience, whereas mammogra-
phy is performed according to strict technical parameters
dictated by BI-RADS® (American College of Radiology, NY
School of Medicine, New York, 2014).15 One possible expla-
nation for our findings is that younger women have faster
growing tumors16 compared with older women, and, in
theory, these rapidly growing tumors may be smaller during
pretreatment evaluation than they are at the moment sur-
gery is performed.
Our data also revealed that clinical Tunderestimationwas
also more common in women with larger tumors, which in
turn suggests that the semitechnical strategy for T estima-
tion has sensitivity flaws. It is important to notice that we
excluded, as per study protocol, patients with clinical ad-
vanced tumors, since these were prescribed neoadjuvant
treatments, although 18 patients with cT4 were included,
probably because they had small tumors with skin involve-
ment, and they were not sent to neoadjuvant chemotherapy.
Table 2 Clinical and pathological staging
Pathological stage
I II III
Clinical stage
ICC ¼ 0.54
I 46 24 8
II 8 60 54
III 0 2 24
Comparison of T staging
T Pathological
1 2 3 4
T clinical
ICC ¼ 0.62
1 64 25 0 4
2 13 68 4 21
3 0 5 1 2
4 0 0 0 18
Mean
(range)
p
Tumor diameter
(pathological,
millimeters)
Correctly
staged
overstaged
25 (1 to
75)
Understaged 32 (12
to 80)
< 0.001
Comparison of N staging
N Pathological
0 1 2 3
N Clinical
ICC ¼ 0.33
0 89 31 11 6
1 17 26 22 19
2 1 0 2 2
3 0 0 0 0
Mean
(range)
p
Number of compromised
lymph nodes
(pathological)
Correctly
staged
overstaged
2.3 (0
to 29)
Understaged 6.9 (0
to 41)
< 0.001
Abbreviations: ICC, intraclass correlation coefficient; N, lymph node
staging; T, tumor staging.
Note: Dark shading, overstaged; light shading, understaged.
Table 3 Staging features as related to age at diagnosis, menopausal status and clinical symptoms
T staging status N staging status
Under
staged
Correctly
staged
Over
staged
p Under
staged
Correctly
staged
Over
staged
p
Age  57 years 18 (33.3) 89 (59.2) 11 (61.1) 41 (46.2) 67 (57.8) 10 (52.6)
Age < 57 years 38 (66.7) 61 (40.8) 7 (38.9) < 0.001 50 (53.8) 49 (42.2) 8 (47.4) 0.18
Menopaused 30 (54.4) 112 (73.9) 15 (83.3) 61 (67.7) 82 (70.1) 14 (73.7)
Not menopaused 26 (45.6) 39 (26.1) 3 (16.7) < 0.01 30 (32.3) 35 (29.9) 4 (26.3) 0.65
Diagnosis by screening 16 (29.8) 58 (38.6) 3 (16.7) 19 (22.6) 52 (44.4) 7 (36.8)
Diagnosis triggered
by symptoms
40 (70.2) 93 (61.4) 15 (83.1) 0.11 72 (77.4) 65 (55.6) 11 (63.2) < 0.001
Abbreviations: N, lymph node staging; T, tumor staging.
Note: Dark shading, overstaged; Light shading, understaged.
Table 4 Clinical and pathological staging according to
molecular surrogates
Luminal
A
Luminal
B
HER2 Triple-
negative
Understaged
(n/%)
33
(38.4)
30
(34.9)
13
(15.1)
10
(11.6)
Correctly
staged (n/%)
47
(36.0)
54
(41.5)
9
(7.0)
20
(15.5)
Overstaged
(n/%)
4
(40.0)
3
(30.0)
1
(10.0)
2
(20.0)
Abbreviation: n, number.
Note: Chi-square (2) p ¼ 0.48.
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We found that out of 93 patients with clinical T1 tumors, 25
were further diagnosedwith pT2 tumors, and another 4,with
pT4 tumors. However, out of the 106 womenwith clinical T2
tumors, 21 were later diagnosed with pT4 disease. These
figures suggest that the clinical evaluation of the breast,
especially in women with larger tumors, may be flawed by
the underestimation of skin and chest wall involvement,
which may pose serious implications for the success of the
primary surgical treatment.
The failure to clinically detect lymph node involvement
was the main responsible reason for the clinical underesti-
mation of the local extension of the disease. The implication
of this must be analyzed with caution, since women with
clinical N0 tumors who were later diagnosed with pN1 or
pN2 do not represent a technical problem, since it is expected
that a percentage of patients, depending on tumor character-
istics, will be in this situation, and sentinel lymph node
biopsy can be used to overcome this situation. The clinical
challenge resides in women who are clinically deemed N1
and are later found to be N2 or N3. For these patients,
suboptimal dissection of the axillary nodes may occur due
to unexpected technical difficulties during surgery. In many
cases, prognosis may be affected, since neoadjuvant treat-
ment might have been a better option, although studies have
shown that treatment order does not seem to be associated
with mortality due to breast cancer.17,18 Recent evidence
from the ACOSOG Z0111 and EORTC AMAROS3 studies have
shown that women with early stage disease may benefit
from less aggressive treatment protocols; however, the
benefits of these less aggressive treatment protocols have
not been demonstrated inwomenwhowere clinically under-
staged.1,3 For instance, in the ACOSOG Z011 trial, women
who were found to have tumors  5 cm on histology were
excluded from analysis.
Overstaging is characterized by the overestimation of
tumor size and spread, and may result in overtreatment. In
our study, 8women (3.5%)were thought to be clinically stage
II but were pathologically stage I, and 2 women (0.9%) were
clinically stage III and were pathologically stage II. We were
unable to determine whether patients who were overstaged
were also overtreated.
Eighty-six (38%) out of 226women had their breast cancer
understaged. However, the number of women who had to
undergo re-operation did not differ betweenwomen correct-
ly staged or overstaged and those understaged. This finding
reveals that clinical understaging of breast tumors was not
associatedwith suboptimal first-line surgical treatment, and
there was no association of clinical understaging with the
rate of re-operations or compromised surgical margins. It is
worth mentioning that there was no significant difference in
the time elapsed from diagnosis to treatment between
patients clinically understaged and those correctly staged
or overstaged. This is an important finding, because signifi-
cantly higher intervals between diagnosis and treatment in
women understaged could have been interpreted as delayed
treatment.
It was our hypothesis that triple-negative, luminal B and
HER2 tumors would be more frequently understaged than
luminal A tumors due to the rapid growth of the former.
However, this hypothesis was not confirmed, and we were
surprised by the fact that younger women, and those who
had their diagnosis triggered by clinical complaints and not
by screening tended to have their tumors understaged more
often. Unfortunately, we do not have annotated follow-up
data for this cohort of patients, and thus it was impossible for
us to evaluate the survival implications of clinical under-
staging, since there were very significant imbalances in
tumor volume and lymph node compromise between
groups.
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